PharmaCyte Biotech (OTCMKTS:PMCBD) and Tenaya Therapeutics (NASDAQ:TNYA) Head to Head Analysis

PharmaCyte Biotech (OTCMKTS:PMCBD) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares PharmaCyte Biotech and Tenaya Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Tenaya Therapeutics	N/A	-86.17%	-71.14%

Risk and Volatility

PharmaCyte Biotech has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500.

Valuation and Earnings

This table compares PharmaCyte Biotech and Tenaya Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Tenaya Therapeutics	N/A	N/A	-$124.08 million	($1.44)	-0.77

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 32.8% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for PharmaCyte Biotech and Tenaya Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	0.00
Tenaya Therapeutics	0	0	6	0	3.00

Tenaya Therapeutics has a consensus price target of $17.33, suggesting a potential upside of 1,461.56%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than PharmaCyte Biotech.

Summary

Tenaya Therapeutics beats PharmaCyte Biotech on 6 of the 9 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.